Fortress Biotech (NASDAQ:FBIO) reduced to “sell” on StockNews.com

Fortress Biotech (NASDAQ:FBIO – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note published Wednesday.

Several other equity analysts have also recently weighed in on FBIO. B. Riley lowered his price target on Fortress Biotech from $8.00 to $6.00 and set a “buy” rating on the stock in a Thursday, July 14 research report. LADENBURG THALM/SH SH began coverage of Fortress Biotech in a research note on Thursday August 4th. They set a “buy” rating and a price target of $6.00 for the company. Finally, Cantor Fitzgerald reiterated a “buy” rating and posted a $6.00 price target on Fortress Biotech shares in a research report on Friday, May 13. One equity research analyst gave the stock a sell rating and six gave the company’s stock a buy rating. According to data from MarketBeat, Fortress Biotech currently has an average rating of “Moderate Buy” and an average target price of $9.60.

Fortress Biotech shares fall 1.0%

FBIO shares opened at $1.04 on Wednesday. The company has a 50-day simple moving average of $0.97 and a two-hundred-day simple moving average of $1.15. The stock has a market capitalization of $112.04 million, a P/E ratio of -0.98 and a beta of 2.10. Fortress Biotech has a 12-month low of $0.77 and a 12-month high of $3.81. The company has a current ratio of 2.85, a quick ratio of 2.70 and a debt ratio of 0.61.

Hedge funds weigh on Fortress Biotech

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new stock position in Fortress Biotech during the fourth quarter, valued at approximately $325,000. Northern Trust Corp increased its position in Fortress Biotech shares by 2.2% during the fourth quarter. Northern Trust Corp now owns 683,283 shares of the biopharmaceutical company valued at $1,708,000 after acquiring an additional 14,470 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Fortress Biotech in the fourth quarter worth $41,000. Lazard Asset Management LLC bought a new stake in Fortress Biotech in the fourth quarter worth $56,000. Finally, Acadian Asset Management LLC acquired a new stake in Fortress Biotech during the fourth quarter at a value of $394,000. 30.92% of the shares are held by hedge funds and other institutional investors.

Fortress Biotech Company Profile

(Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

Recommended Stories

Analyst Recommendations for Fortress Biotech (NASDAQ: FBIO)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fortress Biotech, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Fortress Biotech wasn’t on the list.

Although Fortress Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

About Sally Dominguez

Check Also

Editors Love De La Cruz’s Sulfur Acne Treatment

In my many years working in the beauty industry, I have tried countless trendy treatments …